Compared with atorvastatin at the dose of 10 mg per day rosuvastatin was more effective to reach an LDL goal of < 1.00 g/l in high cardiovascular risk patients (ARIANE study);À la dose identique de 10 mg/j, la rosuvastatine est plus efficace que l'atorvastatine pour atteindre l'objectif de LDL-cholestérol < 1,00 g/l chez les patients à haut risque cardiovasculaire (étude ARIANE)

Annales de Cardiologie et d'Angeiologie

Volumn 56, Issue 2, 2007, Pages 82-87

  Danchin, N ^a   Chadarevian, R ^b   Gayet, J L ^c   Licour, M ^b   Valensi, P ^d  

^a HÔPITAL EUROPÉEN GEORGES POMPIDOU   (France)

^b ASTRAZENECA   (United Kingdom)

^c CNRS Île de France ^*  (France)

^d ASSISTANCE PUBLIQUE HÔPITAUX DE PARIS   (France)

Author keywords

Atorvastatin; Dyslipidemia; High cardiovascular risk; LDL C; Rosuvastatin; Secondary prevention; Statin

Indexed keywords

ATORVASTATIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; ROSUVASTATIN; FLUOROBENZENE; HEPTANOIC ACID DERIVATIVE; HYPOCHOLESTEROLEMIC AGENT; PYRIMIDINE DERIVATIVE; PYRROLE DERIVATIVE; SULFONAMIDE;

ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORONARY RISK; CREATINE KINASE BLOOD LEVEL; DISEASE ASSOCIATION; DISEASE CLASSIFICATION; DRUG TOLERABILITY; DYSLIPIDEMIA; FATIGUE; FEMALE; HIGH RISK PATIENT; HUMAN; LIPOPROTEIN BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; MUSCLE CRAMP; MYALGIA; PRIMARY MEDICAL CARE; RANDOMIZED CONTROLLED TRIAL; RISK FACTOR; SCORING SYSTEM; SECONDARY PREVENTION; SIDE EFFECT; STATISTICAL SIGNIFICANCE; THERAPY EFFECT; TREATMENT OUTCOME; TREATMENT RESPONSE; BLOOD; DOSE RESPONSE; MIDDLE AGED;

ANTICHOLESTEREMIC AGENTS; CHOLESTEROL, LDL; DOSE-RESPONSE RELATIONSHIP, DRUG; DYSLIPIDEMIAS; FEMALE; FLUOROBENZENES; HEPTANOIC ACIDS; HUMANS; MALE; MIDDLE AGED; PYRIMIDINES; PYRROLES; SULFONAMIDES;

EID: 33947313278     PISSN: 00033928     EISSN: 17683181     Source Type: Journal    
DOI: 10.1016/j.ancard.2007.01.003     Document Type: Article

References (24)

1. Baigent C., Keech A., Kearney P.M., et al. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet 366 (2005) 1267-1278
2. Pearson T.A., Laurora I., Chu H., and Kafonek S. The lipid treatment assessment project (L-TAP): a multicenter survey to evaluate the percentages of dyslipidemic patients receiving lipid-lowering therapy and achieving low-density lipoprotein cholesterol goals. Arch. Intern. Med. 160 (2000) 459-467
3. Ferrieres J., Elbaz M., Maupas E., Carrie D., and Puel J. Insuffisance de la prise en charge des patients dyslipidémiques en France. Arch. Mal. Coeur Vaiss. 97 (2004) 187-193
4. Amouyel P., Lamarque H., and Gayet J.L. [Treatment with statins in general medicine: dosage and effectiveness]. Arch. Mal. Coeur Vaiss. 98 (2005) 1206-1211
5. Anderson K.M., Wilson P.W., Odell P.M., and Kannel W.B. An updated coronary risk profile. A statement for health professionals. Circulation 83 (1991) 356-362
6. Méthodes d'évaluation du risque cardiovasculaire global. Agence nationale d'accréditation et d'évaluation de santé (Anaes). Paris. 2004. Available from: www.anaes.fr.
7. Recommandations de bonne pratique clinique. Prise en charge thérapeutique des patients dyslipidémiques. Agence française de sécurité sanitaire des produits de santé (Afssaps). Paris. 2000. Available from: http://agmed.sante.gouv.fr/htm/5/rbp/5552c.htm.
8. Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection. Evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III). JAMA 285 (2001) 2486-2497
9. Prevention of coronary heart disease in clinical practice. Recommendations of the Second Joint Task Force of European and other Societies on coronary prevention. Eur. Heart J. 19 (1998) 1434-1503
10. Delahaye F., Bory M., Cohen A., et al. Recommandations de la Société française de cardiologie concernant la prise en charge de l'infarctus du myocarde après la phase aiguë. Arch. Mal. Coeur Vaiss. 94 (2001) 697-738
11. Brown A.S., Bakker-Arkema R.G., Yellen L., et al. Treating patients with documented atherosclerosis to National Cholesterol Education Program-recommended low-density-lipoprotein cholesterol goals with atorvastatin, fluvastatin, lovastatin and simvastatin. J. Am. Coll. Cardiol. 32 (1998) 665-672
12. Davidson M., Ma P., Stein E.A., et al. Comparison of effects on low-density lipoprotein cholesterol and high-density lipoprotein cholesterol with rosuvastatin versus atorvastatin in patients with type IIa or IIb hypercholesterolemia. Am. J. Cardiol. 89 (2002) 268-275
13. Paoletti R., Fahmy M., Mahla G., Mizan J., and Southworth H. Rosuvastatin demonstrates greater reduction of low-density lipoprotein cholesterol compared with pravastatin and simvastatin in hypercholesterolaemic patients: a randomized, double-blind study. J. Cardiovasc. Risk 8 (2001) 383-390
14. Recommandations de bonne pratique clinique. Prise en charge thérapeutique du patient dyslipidémique. Agence française de sécurité sanitaire des produits de santé (Afssaps). Paris. 2005. Available from: http://agmed.sante.gouv.fr/pdf/5/rbp/dysreco.pdf.
15. Kramer H.J., Nguyen Q.D., Curhan G., and Hsu C.Y. Renal insufficiency in the absence of albuminuria and retinopathy among adults with type 2 diabetes mellitus. JAMA 289 (2003) 3273-3277
16. Crestor. Résumé des caractéristiques du produit. 2000. Available from: http://agmed.sante.gouv.fr/htm/1/amm/amm0.htm.
17. Fonseca F.A., Ruiz A., Cardona-Munoz E.G., Silva J.M., Fuenmayor N., and Marotti M. The DISCOVERY PENTA study: a DIrect Statin COmparison of LDL-C Value--an Evaluation of Rosuvastatin therapY compared with atorvastatin. Curr. Med. Res. Opin. 21 (2005) 1307-1315
18. Valensi P., Danchin N., Hannachi H., and Chadarevian R. La rosuvastatine 10 mg est plus efficace que la simvastatine 20 mg pour atteindre l'objectif recommandé de LDL-C Congrès annuel de l'ALFEDIAM. Diabetes Metab. 32 (2006) 1S39-1S112
19. Vanuzzo D., Pilotto L., Ambrosio G.B., et al. Potential for cholesterol lowering in secondary prevention of coronary heart disease in europe: findings from EUROASPIRE study. European Action on Secondary Prevention through Intervention to Reduce Events. Atherosclerosis 153 (2000) 505-517
20. Vale M.J., Jelinek M.V., and Best J.D. How many patients with coronary heart disease are not achieving their risk-factor targets? Experience in Victoria 1996-1998 versus 1999-2000. Med. J. Aust. 176 (2002) 211-215
21. Ferrieres J., Lablanche J., Pouchain D., et al. Évaluation biologique du traitement hypolipémiant en France. Étude SPOT. Arch. Mal. Coeur Vaiss. 98 (2005) 58-62
22. McKenney J.M., Davidson M.H., Jacobson T.A., and Guyton J.R. Final conclusions and recommendations of the National Lipid Association Statin Safety Assessment Task Force. Am. J. Cardiol. 97 (2006) 89C-94C
23. de Lemos J.A., Blazing M.A., Wiviott S.D., et al. Early intensive vs a delayed conservative simvastatin strategy in patients with acute coronary syndromes: phase Z of the A to Z trial. JAMA 292 (2004) 1307-1316
24. Cannon C.P., Braunwald E., McCabe C.H., et al. Intensive versus moderate lipid lowering with statins after acute coronary syndromes. N. Engl. J. Med. 350 (2004) 1495-1504